Logo

RVPH

Reviva Pharmaceuticals Holdings, Inc.

RVPH

Reviva Pharmaceuticals Holdings, Inc. • NASDAQ
$0.56 ▲ 7.66% (+0.04)
Market Cap $38.35 M
52w High $4.28
52w Low $0.25
Dividend Yield 0%
P/E -1.28
Volume 3.97M
Outstanding Shares 68.18M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $0 $6.073M ▼ $-6.054M ▲ 0% $-0.12 ▲ $-6.041M ▲
Q1-2025 $0 $6.538M ▲ $-6.433M ▼ 0% $-0.13 ▲ $-6.416M ▼
Q4-2024 $0 $6.285M ▼ $-6.259M ▲ 0% $-0.147 ▲ $-6.25M ▼
Q3-2024 $0 $8.463M ▲ $-8.366M ▼ 0% $-0.247 ▲ $0 ▲
Q2-2024 $0 $8.13M $-7.86M 0% $-0.257 $-7.565M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $10.364M ▲ $11.635M ▲ $12.094M ▲ $-459.147K ▲
Q1-2025 $5.289M ▼ $7.077M ▼ $11.537M ▼ $-4.46M ▼
Q4-2024 $13.476M ▲ $15.503M ▲ $14.691M ▼ $812.572K ▲
Q3-2024 $5.559M ▼ $7.63M ▼ $17.612M ▲ $-9.982M ▼
Q2-2024 $6.178M $8.053M $14.094M $-6.042M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-6.054M ▲ $-5.013M ▲ $0 $10.087M ▲ $5.074M ▲ $-5.013M ▲
Q1-2025 $-6.433M ▼ $-8.194M ▲ $0 $7.271K ▼ $-8.187M ▼ $-8.194M ▲
Q4-2024 $-6.259M ▲ $-9.1M ▼ $0 $17.018M ▲ $7.918M ▲ $-9.1M ▼
Q3-2024 $-8.366M ▼ $-4.241M ▲ $0 $3.622M ▲ $-619.363K ▲ $-4.241M ▲
Q2-2024 $-7.86M $-8.476M $0 $2.681M $-5.795M $-8.476M

Five-Year Company Overview

Income Statement

Income Statement Reviva is still a pure research-stage biotech, with no product revenue yet and a track record of steady losses. Its costs are mainly tied to R&D and running clinical programs, so expenses have risen as the pipeline has advanced. Losses per share have been consistently negative, reflecting the company’s investment phase rather than any established commercial business. Overall, the income statement shows a classic early‑stage biotech profile: all spend, no sales, and financial results driven by trial activity and financing, not operations.

Balance Sheet

Balance Sheet The balance sheet is small and simple, with most assets sitting in cash and no traditional debt reported. Equity is modest and has fluctuated as the company funds itself, which is typical for a micro‑cap, clinical‑stage biotech. The absence of debt reduces interest burden but also underscores that the company relies heavily on equity and similar financings. The overall picture is a lean capital structure with limited resources that will need to be refreshed as development spending continues.

Cash Flow

Cash Flow Cash flows reflect consistent outflows from operations as the company pays for trials, personnel, and overhead without any offsetting product income. There is little to no spending on physical assets, so almost all cash usage is tied directly to R&D and corporate costs. Free cash flow has been negative across the period, meaning the business depends on external funding rather than self‑generated cash. This pattern is typical but also highlights ongoing liquidity risk if capital markets or partners are not available when needed.

Competitive Edge

Competitive Edge Reviva is trying to carve out a focused niche in central nervous system disorders, led by its main drug candidate brilaroxazine. The potential edge lies in a differentiated mechanism, promising safety profile, and the ability to address more than just the most obvious symptoms of schizophrenia. Intellectual property and orphan drug designations add some protection and potential exclusivity, while the “pipeline in a pill” strategy aims to spread value across multiple diseases. At the same time, Reviva is small, lacks commercial infrastructure, and competes against much larger pharmaceutical companies with deep resources and existing antipsychotic franchises, making execution and partnering especially important. The company is also highly concentrated in one lead asset, so its competitive position is closely tied to the ultimate clinical and regulatory outcome of brilaroxazine.

Innovation and R&D

Innovation and R&D Innovation is the core of Reviva’s story. Its in‑house chemical genomics platform is designed to engineer drugs that act on multiple targets in a controlled way, which is particularly relevant for complex brain and inflammatory disorders. Brilaroxazine, the lead asset, has shown encouraging late‑stage data in schizophrenia and is being positioned for a broad range of additional conditions, from mood disorders to pulmonary and inflammatory diseases. A second program, RP1208, supports the idea that the platform can generate more than one viable drug, though it is still at an earlier stage. Overall, the R&D strategy is ambitious and science‑driven, but entirely dependent on ongoing trial success and regulatory acceptance, which are inherently uncertain.

Summary

Reviva is a high‑risk, high‑uncertainty, clinical‑stage biotech built around a single, advanced drug candidate and a specialized discovery platform. Financially, it has no revenue, persistent losses, and ongoing cash burn, with a thin but clean balance sheet and a clear need for future funding as programs progress. Scientifically, it has a potentially differentiated therapy with broad indication reach and supportive regulatory signals so far, but no approved products and significant development risk ahead. The company’s future will be shaped by upcoming clinical milestones, regulatory interactions, and its ability to secure partnerships or capital, making its profile more binary than that of a diversified pharma business. This analysis is descriptive and interpretive only and should not be taken as a view on whether to buy, sell, or hold the stock.

NEWS

November 13, 2025 · 4:05 PM UTC

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Read more

October 28, 2025 · 8:00 AM UTC

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

Read more

October 7, 2025 · 4:08 PM UTC

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Read more

September 18, 2025 · 9:26 PM UTC

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Read more

September 18, 2025 · 4:05 PM UTC

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Read more